We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01655680
Recruitment Status : Completed
First Posted : August 2, 2012
Last Update Posted : May 15, 2015
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )

Brief Summary:
This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: ABT-126 Drug: Placebo Phase 2

Detailed Description:
This is a Phase 2 study designed to evaluate the safety and efficacy of ABT-126 in treating cognitive deficits in subjects with a diagnosis of schizophrenia. Eligible subjects will take study drug as an add-on treatment to their ongoing antipsychotic treatment regimen.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 432 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers
Study Start Date : May 2012
Primary Completion Date : April 2014
Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arm Intervention/treatment
Experimental: ABT-126 Low Dose
ABT-126 Low Dose
Drug: ABT-126
ABT-126 Low Dose
Experimental: ABT-126 Middle Dose
ABT-126 Middle Dose
Drug: ABT-126
ABT-126 Middle Dose
Experimental: ABT-126 High Dose
ABT-126 High Dose
Drug: ABT-126
ABT-126 High Dose
Placebo Comparator: Placebo
Drug: Placebo

Primary Outcome Measures :
  1. Cognition: MCCB (MATRICS Consensus Cognitive Battery) [ Time Frame: Change from baseline to week 24 ]
    Rater based interview

Secondary Outcome Measures :
  1. Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2) [ Time Frame: Measurements from screening period up through week 24 ]
    Rater based interview

  2. Symptom Severity: PANSS (Positive and Negative Symptom Scale) [ Time Frame: Measurements from screening period up through week 24 ]
    Rater based interview

  3. Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale) [ Time Frame: Measurements from screening period up through week 24 ]
    Rater based interview

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has a current Diagnostic and Statistical Manual of Mental Disorders-, 4th Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).
  • Is clinically stable while receiving a regimen of one or two allowable antipsychotic medications: lack of hospitalizations in 4 months prior to initial screening visit; taking the same antipsychotic medication(s) for at least 8 weeks prior to baseline visit; core positive symptoms of Positive and Negative Syndrome Scale (PANSS) no worse than moderate in severity throughout screening period of at least 4 weeks.
  • Has been diagnosed with or treated for schizophrenia for at least 2 years prior to initial screening visit.
  • Has had continuity in psychiatric care (e.g., mental health system, clinic or physician) for at least 6 months prior to initial screening visit.
  • Has an identified contact person (e.g., family member, social worker, case worker, or nurse) that can provide support to the subject to ensure compliance with protocol requirements.

Exclusion Criteria:

  • In the Investigator's judgment, has a current or past diagnosis of schizoaffective disorder, bipolar disorder, manic episode, dementia, post traumatic stress disorder, or obsessive-compulsive disorder, or the subject has a current major depressive episode.
  • Has a positive urine drug screen for cocaine, phencyclidine (PCP), opiates (unless duly prescribed), benzodiazepines (unless duly prescribed), marijuana, or amphetamines during the Screening Period.
  • Has a current or past history of seizures, with the exception of a single febrile seizure occurring prior to 6 years of age.
  • Has a clinically significant abnormal electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator.
  • Has any risk factors for Torsades de Pointes (TdP)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655680

  Show 61 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: George Haig, PharmD AbbVie

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AbbVie (prior sponsor, Abbott)
ClinicalTrials.gov Identifier: NCT01655680     History of Changes
Other Study ID Numbers: M10-855
2012-000418-13 ( EudraCT Number )
First Posted: August 2, 2012    Key Record Dates
Last Update Posted: May 15, 2015
Last Verified: April 2015

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Additional relevant MeSH terms:
Cognition Disorders
Cognitive Dysfunction
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Neurocognitive Disorders